326030 — SK Biopharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩7tn
- KR₩7tn
- KR₩355bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 123,852 | 25,999 | 418,645 | 246,179 | 354,892 |
Cost of Revenue | |||||
Gross Profit | 123,338 | 24,025 | 396,309 | 208,411 | 320,809 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 203,111 | 265,498 | 274,417 | 372,940 | 387,106 |
Operating Profit | -79,259 | -239,499 | 144,227 | -126,761 | -32,214 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -84,451 | -239,909 | 71,277 | -142,469 | -43,858 |
Provision for Income Taxes | |||||
Net Income After Taxes | -71,519 | -247,414 | 64,846 | -139,431 | -35,379 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -71,519 | -247,414 | 64,846 | -139,431 | -32,883 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -71,519 | -247,414 | 64,846 | -139,431 | -32,883 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,080 | -3,448 | 256 | -1,816 | -464 |
Dividends per Share |